Smallpox-Pipeline Review, H1 2015

Smallpox-Pipeline Review, H1 2015

  • Products Id :- GMDHC6170IDB
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Smallpox-Pipeline Review, H1 2015


Global Markets Direct's, 'Smallpox-Pipeline Review, H1 2015', provides an overview of the Smallpox's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Smallpox

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Smallpox

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Smallpox Overview 8

Therapeutics Development 9

Pipeline Products for Smallpox-Overview 9

Pipeline Products for Smallpox-Comparative Analysis 10

Smallpox-Therapeutics under Development by Companies 11

Smallpox-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Smallpox-Products under Development by Companies 17

Smallpox-Companies Involved in Therapeutics Development 18

AlphaVax, Inc. 18

Bavarian Nordic A/S 19

CEL-SCI Corporation 20

Chimerix, Inc. 21

CJ CheilJedang Corp. 22

EpiVax, Inc. 23

Inovio Pharmaceuticals, Inc. 24

MacroGenics, Inc. 25

Nanotherapeutics, Inc. 26

Oncovir, Inc. 27

SIGA Technologies, Inc. 28

Symphogen A/S 29

TapImmune Inc. 30

Tonix Pharmaceuticals Holding Corp. 31

Smallpox-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

brincidofovir-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CEL-1000-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

cidofovir-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

CJ-50300-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

imatinib mesylate-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Monoclonal Antibodies for Infectious Disease-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

PL-801-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Poly-ICLC-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

small pox vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

smallpox (multivalent) vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

smallpox vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

smallpox vaccine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

smallpox vaccine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Sym-002-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

tecovirimat-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

TPIV-300-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Smallpox-Recent Pipeline Updates 63

Smallpox-Dormant Projects 76

Smallpox-Discontinued Products 77

Smallpox-Product Development Milestones 78

Featured News & Press Releases 78

Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 78

Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 78

Dec 23, 2014: Chimerix Provides Recap of 2014 Events 78

Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 80

Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox 80

Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine 81

Aug 10, 2014: Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages 81

Jul 31, 2014: New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients 82

Jul 08, 2014: Chimerix Announces Three Abstracts to be Presented at the 2014 World Transplant Congress 83

Apr 22, 2014: Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 85

List of Tables

Number of Products under Development for Smallpox, H1 2015 9

Number of Products under Development for Smallpox-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Smallpox-Pipeline by AlphaVax, Inc., H1 2015 18

Smallpox-Pipeline by Bavarian Nordic A/S, H1 2015 19

Smallpox-Pipeline by CEL-SCI Corporation, H1 2015 20

Smallpox-Pipeline by Chimerix, Inc., H1 2015 21

Smallpox-Pipeline by CJ CheilJedang Corp., H1 2015 22

Smallpox-Pipeline by EpiVax, Inc., H1 2015 23

Smallpox-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 24

Smallpox-Pipeline by MacroGenics, Inc., H1 2015 25

Smallpox-Pipeline by Nanotherapeutics, Inc., H1 2015 26

Smallpox-Pipeline by Oncovir, Inc., H1 2015 27

Smallpox-Pipeline by SIGA Technologies, Inc., H1 2015 28

Smallpox-Pipeline by Symphogen A/S, H1 2015 29

Smallpox-Pipeline by TapImmune Inc., H1 2015 30

Smallpox-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

Smallpox Therapeutics-Recent Pipeline Updates, H1 2015 63

Smallpox-Dormant Projects, H1 2015 76

Smallpox-Discontinued Products, H1 2015 77

List of Figures

Number of Products under Development for Smallpox, H1 2015 9

Number of Products under Development for Smallpox-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 33

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AlphaVax, Inc.

Bavarian Nordic A/S

CEL-SCI Corporation

Chimerix, Inc.

CJ CheilJedang Corp.

EpiVax, Inc.

Inovio Pharmaceuticals, Inc.

MacroGenics, Inc.

Nanotherapeutics, Inc.

Oncovir, Inc.

SIGA Technologies, Inc.

Symphogen A/S

TapImmune Inc.

Tonix Pharmaceuticals Holding Corp.

Smallpox Therapeutic Products under Development, Key Players in Smallpox Therapeutics, Smallpox Pipeline Overview, Smallpox Pipeline, Smallpox Pipeline Assessment

select a license

Single User License
USD 2000 INR 132400
Site License
USD 4000 INR 264800
Corporate User License
USD 6000 INR 397200



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]